Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule
Open Access
- 1 January 1984
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 49 (1), 43-47
- https://doi.org/10.1038/bjc.1984.7
Abstract
Very high dose cyclophosphamide (Cy) (500-600 mg kg-1) given by single bolus i.p. injection in mice caused acute deaths in all animals within 48 h of treatment (0/10 survivors). These acute deaths were abolished or very significantly reduced if Cy was administered in divided dosage over 8 h (10/10 survivors) or 12 h (14/15 survivors). The effect was maintained at doses of up to 600 mg kg-1 administered in divided dosage over 24 h (15/15 survivors). In 2 human small cell carcinoma xenografts anti-tumour efficacy was not diminished by divided dosage. In both xenografts tumour growth delay was enhanced, although not significantly so, when treated with divided dosage compared with single dose, and in one of the xenografts 3 complete remissions were achieved with divided dosage compared with none after single dosage. It is postulated that the underlying mechanism concerns diminished cardiotoxicity. These results may have significance in clinical studies investigating very high dose Cy.Keywords
This publication has 11 references indexed in Scilit:
- Faculty Opinions recommendation of Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.Published by H1 Connect ,2014
- The human tumour xenograft—a valid model in experimental chemotherapy?British Journal of Surgery, 1980
- Cyclophosphamide-induced lung damage in mice: protection by a small preliminary doseBritish Journal of Cancer, 1980
- Lung damage from cytotoxic drugsCancer Chemotherapy and Pharmacology, 1980
- Improved immune-suppression techniques for the xenografting of human tumoursBritish Journal of Cancer, 1978
- Combinations of Cytotoxic Agents that have less than Expected Toxicity on Normal Tissues in MicePublished by S. Karger AG ,1977
- Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.1974
- Cyclophosphamide. Drug interactions and bone marrow transplantation.1972
- Cyclophosphamide in Treatment of Disseminated Malignant DiseaseBMJ, 1961
- Cyclophosphamide and urinary bladder toxicity.1961